Full Text:   <1231>

Summary:  <1406>

Suppl. Mater.: 

CLC number: 

On-line Access: 2021-04-08

Received: 2020-11-15

Revision Accepted: 2021-01-27

Crosschecked: 2021-03-16

Cited: 0

Clicked: 3158

Citations:  Bibtex RefMan EndNote GB/T7714

 ORCID:

Shufa ZHENG

https://orcid.org/0000-0003-2536-1008

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2021 Vol.22 No.4 P.330-340

http://doi.org/10.1631/jzus.B2000730


Effects of angiotensin II receptor blocker usage on viral load, antibody dynamics, and transcriptional characteristics among COVID-19 patients with hypertension


Author(s):  Baihuan FENG, Dan ZHANG, Qi WANG, Fei YU, Qianda ZOU, Guoliang XIE, Ruonan WANG, Xianzhi YANG, Weizhen CHEN, Bin LOU, Shufa ZHENG, Yu CHEN

Affiliation(s):  Department of Laboratory Medicine, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; more

Corresponding email(s):   zsfzheng@zju.edu.cn

Key Words:  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Coronavirus disease 2019 (COVID-19), Renin-angiotensin system (RAS), Angiotensin-converting enzyme 2 (ACE2), Hypertension


Share this article to: More <<< Previous Article|

Baihuan FENG, Dan ZHANG, Qi WANG, Fei YU, Qianda ZOU, Guoliang XIE, Ruonan WANG, Xianzhi YANG, Weizhen CHEN, Bin LOU, Shufa ZHENG, Yu CHEN. Effects of angiotensin II receptor blocker usage on viral load, antibody dynamics, and transcriptional characteristics among COVID-19 patients with hypertension[J]. Journal of Zhejiang University Science B, 2021, 22(4): 330-340.

@article{title="Effects of angiotensin II receptor blocker usage on viral load, antibody dynamics, and transcriptional characteristics among COVID-19 patients with hypertension",
author="Baihuan FENG, Dan ZHANG, Qi WANG, Fei YU, Qianda ZOU, Guoliang XIE, Ruonan WANG, Xianzhi YANG, Weizhen CHEN, Bin LOU, Shufa ZHENG, Yu CHEN",
journal="Journal of Zhejiang University Science B",
volume="22",
number="4",
pages="330-340",
year="2021",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2000730"
}

%0 Journal Article
%T Effects of angiotensin II receptor blocker usage on viral load, antibody dynamics, and transcriptional characteristics among COVID-19 patients with hypertension
%A Baihuan FENG
%A Dan ZHANG
%A Qi WANG
%A Fei YU
%A Qianda ZOU
%A Guoliang XIE
%A Ruonan WANG
%A Xianzhi YANG
%A Weizhen CHEN
%A Bin LOU
%A Shufa ZHENG
%A Yu CHEN
%J Journal of Zhejiang University SCIENCE B
%V 22
%N 4
%P 330-340
%@ 1673-1581
%D 2021
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2000730

TY - JOUR
T1 - Effects of angiotensin II receptor blocker usage on viral load, antibody dynamics, and transcriptional characteristics among COVID-19 patients with hypertension
A1 - Baihuan FENG
A1 - Dan ZHANG
A1 - Qi WANG
A1 - Fei YU
A1 - Qianda ZOU
A1 - Guoliang XIE
A1 - Ruonan WANG
A1 - Xianzhi YANG
A1 - Weizhen CHEN
A1 - Bin LOU
A1 - Shufa ZHENG
A1 - Yu CHEN
J0 - Journal of Zhejiang University Science B
VL - 22
IS - 4
SP - 330
EP - 340
%@ 1673-1581
Y1 - 2021
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2000730


Abstract: 
Epidemiological evidence suggests that patients with hypertension infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are at increased risk of acute lung injury. However, it is still not clear whether this increased risk is related to the usage of renin-angiotensin system (RAS) blockers. We collected medical records of coronavirus disease 2019 (COVID-19) patients from the First Affiliated Hospital, Zhejiang University School of Medicine (Hangzhou, China), and evaluated the potential impact of an angiotensin II receptor blocker (ARB) on the clinical outcomes of COVID-19 patients with hypertension. A total of 30 hypertensive COVID-19 patients were enrolled, of which 17 were classified as non-ARB group and the remaining 13 as ARB group based on the antihypertensive therapies they received. Compared with the non-ARB group, patients in the ARB group had a lower proportion of severe cases and intensive care unit (ICU) admission as well as shortened length of hospital stay, and manifested favorable results in most of the laboratory testing. Viral loads in the ARB group were lower than those in the non-ARB group throughout the disease course. No significant difference in the time of seroconversion or antibody levels was observed between the two groups. The median levels of soluble angiotensin-converting enzyme 2 (sACE2) in serum and urine samples were similar in both groups, and there were no significant correlations between serum sACE2 and biomarkers of disease severity. Transcriptional analysis showed 125 differentially expressed genes which mainly were enriched in oxygen transport, bicarbonate transport, and blood coagulation. Our results suggest that ARB usage is not associated with aggravation of COVID-19. These findings support the maintenance of ARB treatment in hypertensive patients diagnosed with COVID-19.

血管紧张素受体阻滞剂使用对COVID-19高血压患者病毒载量、抗体水平和转录特征的影响

目的:评估血管紧张素受体阻滞剂(ARB)的使用对新型冠状病毒肺炎(COVID-19)高血压患者疾病转归的影响。
创新点:揭示了ARB使用对COVID-19高血压患者病毒载量和抗体水平动态变化过程的影响,进一步利用转录组学揭示了ARB使用后基因表达谱的变化对疾病转归的影响。
方法:收集浙江大学医学院附属第一医院COVID-19高血压患者病历资料,分析并评估ARB使用对COVID-19高血压患者病毒载量、抗体水平和转录特征的影响。
结论:ARB使用与COVID-19高血压患者病情加重不存在相关性:ARB使用显著降低COVID-19高血压患者病毒持续时间与病毒载量;ARB使用对抗体水平以及可溶性血管紧张素转换酶2(ACE2)水平无显著影响;转录组分析显示,两组差异基因主要富集于氧转运、碳酸氢盐转运和血凝等。

关键词:新型冠状病毒;新型冠状病毒肺炎(COVID-19);肾素-血管紧张素系统:血管紧张素转换酶2(ACE2);高血压

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]BeanDM, KraljevicZ, SearleT, et al., 2020. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust. Eur J Heart Fail, 22(6):967-974.

[2]CoxRJ, BrokstadKA, 2020. Not just antibodies: B cells and T cells mediate immunity to COVID-19. Nat Rev Immunol, 20(10):581-582.

[3]FangL, KarakiulakisG, RothM, 2020. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med, 8(4):e21.

[4]FosbolEL, ButtJH, ØstergaardL, et al., 2020. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. JAMA, 324(2):168-177.

[5]GaoC, CaiY, ZhangK, et al., 2020. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J, 41(22):2058-2066.

[6]GrasselliG, GrecoM, ZanellaA, et al., 2020. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med, 180(10):1345-1355.

[7]ImaiY, KubaK, RaoS, et al., 2005. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature, 436(7047):112-116.

[8]KreutzR, EAEHAlgharably, AziziM, et al., 2020. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19: European Society of Hypertension COVID-19 Task Force Review of Evidence. Cardiovasc Res, 116(10):1688-1699.

[9]KubaK, ImaiY, RaoS, et al., 2005. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med, 11(8):875-879.

[10]LamKW, ChowKW, VoJ, et al., 2020. Continued in-hospital angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use in hypertensive COVID-19 patients is associated with positive clinical outcome. J Infect Dis, 222(8):1256-1264.

[11]LanJ, GeJW, YuJF, et al., 2020. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature, 581(7807):215-220.

[12]LeviM, ThachilJ, IbaT, et al., 2020. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol, 7(6):e438-e440.

[13]LiaoDY, ZhouF, LuoLL, et al., 2020. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol, 7(9):e671-e678.

[14]LiuX, SperanzaE, Munoz-FontelaC, et al., 2017. Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virus. Genome Biol, 18:4.

[15]MackeyK, KingVJ, GurleyS, et al., 2020. Risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults: a living systematic review. Ann Intern Med, 173(3):195-203.

[16]ManciaG, ReaF, LudergnaniM, et al., 2020. Renin-angiotensin-aldosterone system blockers and the risk of COVID-19. New Engl J Med, 382(25):2431-2440.

[17]MehtaN, KalraA, NowackiAS, et al., 2020. Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol, 5(9):1020-1026.

[18]MengJ, XiaoGH, ZhangJJ, et al., 2020. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect, 9(1):757-760.

[19]National Health Commission of the People’s Republic of China, 2020. Guideline for diagnosis and treatment of SARS-CoV-2 (the 7th edition). http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml(in Chinese).

[20]PintoBGG, OliveiraAER, SinghY, et al., 2020. ACE2 expression is increased in the lungs of patients with comorbidities associated with severe COVID-19. J Infect Dis, 222(4):556-563.

[21]RomagnoliS, PerisA, de GaudioAR, et al., 2020. SARS-CoV-2 and COVID-19: from the bench to the bedside. Physiol Rev, 100(4):1455-1466.

[22]ShangJ, YeG, ShiK, et al., 2020. Structural basis of receptor recognition by SARS-CoV-2. Nature, 581(7807):221-224.

[23]VistisenST, BodilsenJ, ScheerenTWL, et al., 2020. Risk and prognosis of COVID-19 in patients treated with renin-angiotensin-aldosterone inhibitors. Eur J Anaesthesiol, 37(9):739-742.

[24]World Health Organization, 2020. Coronavirus disease (COVID-19): weekly epidemiological update and weekly operational update. Technical Report. World Health Organization, Geneva. https://www.who.int/publications/m/item/weekly-epidemiological-update---16-march-2021

[25]WrappD, WangNS, CorbettKS, et al., 2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 367(6483):1260-1263.

[26]YangG, TanZH, ZhouL, et al., 2020. Effects of angiotensin II receptor blockers and ACE (angiotensin-converting enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: a single-center retrospective study. Hypertension, 76(1):51-58.

[27]ZhangJS, WangML, DingW, et al., 2020. The interaction of RAAS inhibitors with COVID-19: current progress, perspective and future. Life Sci, 257:118142.

[28]ZhangP, ZhuLH, CaiJJ, et al., 2020. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res, 126(12):1671-1681.

[29]ZhengSF, FanJ, YuF, et al., 2020. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang Province, China, January‒March 2020: retrospective cohort study. BMJ, 369:m1443.

[30]ZhengYY, MaYT, ZhangJY, et al., 2020. COVID-19 and the cardiovascular system. Nat Rev Cardiol, 17(5):259-260.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2022 Journal of Zhejiang University-SCIENCE